Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current treatment recommendations in antiarrhythmic therapy

I C Van Gelder1, J Brügemann, H J Crijns

  • 1Department of Cardiology, Thoraxcenter, University Hospital Groningen, The Netherlands. I.C.Van.Gelder@thorax.azg.nl

Drugs
|April 8, 1998
PubMed
Summary

Class I antiarrhythmic drugs are contraindicated in heart failure. Beta-blockers (Class II) improve outcomes, while Class III drugs like amiodarone treat arrhythmias but don't lower mortality. Implantable cardioverter defibrillators show promise for life-threatening arrhythmias.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk prediction of atrial fibrillation progression in patients with paroxysmal atrial fibrillation: data from the RACE V study.

International journal of cardiology. Heart & vasculature·2026
Same author

External validation and updating of prediction models of bleeding risk in patients with cancer receiving anticoagulants.

Open heart·2023
Same author

Increased plasma levels of NT-proBNP, Troponin T and GDF-15 are driven by persistent AF and associated comorbidities: Data from the AF-RISK study.

International journal of cardiology. Heart & vasculature·2022
Same author

Heart rate increase and inappropriate sinus tachycardia after cryoballoon pulmonary vein isolation for atrial fibrillation.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2021
Same author

Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST).

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2021
Same author

Gut-microbe derived TMAO and its association with more progressed forms of AF: Results from the AF-RISK study.

International journal of cardiology. Heart & vasculature·2021

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Class I antiarrhythmic drugs are associated with adverse outcomes in patients with heart failure, myocardial infarction, or cardiac ischemia.
  • Beta-blockers (Class II) have demonstrated benefits in reducing morbidity and mortality in heart failure patients.

Purpose of the Study:

  • To review the current evidence on the use of different antiarrhythmic drug classes in patients with heart failure and arrhythmias.
  • To discuss the role of amiodarone, pure Class III agents, calcium channel blockers (Class IV), and implantable cardioverter defibrillators in managing cardiac arrhythmias.

Main Methods:

  • Literature review of studies on antiarrhythmic drug efficacy and safety in cardiovascular conditions.
  • Analysis of clinical trial data and expert consensus regarding drug classes and devices.

Related Experiment Videos

Main Results:

  • Class I drugs should be avoided in specific cardiac conditions. Beta-blockers are beneficial in heart failure. Amiodarone effectively treats symptomatic ventricular arrhythmias but does not improve overall survival. Pure Class III drugs carry a risk of torsades de pointes. Calcium channel blockers are useful for atrial fibrillation and certain tachycardias.
  • Implantable cardioverter defibrillators may improve survival in patients with life-threatening ventricular arrhythmias, pending further study data.

Conclusions:

  • Treatment decisions for arrhythmias in heart failure require careful consideration of drug class, specific patient conditions, and potential risks versus benefits.
  • While certain antiarrhythmic drugs and devices offer therapeutic advantages, their prophylactic use is not always indicated, and ongoing research is crucial.